The future of cancer treatment: Exploiting cancer’s key vulnerabilities
By Victoria Zazulina, M.D., head of development unit, oncology, for the healthcare business of Merck…
February 1, 2023 - 4 minutes
Merck
Mersana Therapeutics and Merck to develop novel ADCs
Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary…
December 23, 2022 - 3 minutes
Merck and Kelun-Biotech collaborating on seven ADC cancer candidates
Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan…
December 23, 2022 - 2 minutes
Sponsored
by Merck
Infographic: your gene therapy manufacturing success recipe
By 2026, pharma industry insiders anticipate cell and gene therapy sales to significantly increase, with…
November 14, 2022 - 2 minutes
Merck contributing to Jacobio Pharma colorectal cancer clinical trial
Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on a…
October 13, 2022 - 2 minutes
TILT and MSD working on immunotherapy trial for non-small cell lung cancer
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, has signed a second clinical trial…
September 26, 2022 - 3 minutes
Astellas, Seagen and Merck give details on urothelial cancer treatment
Astellas Pharma Inc., Seagen Inc. and Merck (known as MSD outside of the U.S. and…
September 12, 2022 - 5 minutes
Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies
An investment of €130 million ($130 million) has been invested in Molsheim, France to strengthen…
September 8, 2022 - 2 minutes
CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded
Sigma-Aldrich Co LLC, along with genOway, a preclinical research model space company, announced today (September…
September 8, 2022 - 3 minutes
Merck puts up to $37B into Orna Therapeutics circular RNA collaboration
Merck, also known as MSD outside the U.S. and Canada, and Orna Therapeutics, a biotech…
August 16, 2022 - 3 minutes
Immutep reports positive data from cancer study
Immutep Limited, an Australian biotech company developing LAG-3-related immunotherapy treatments for cancer and autoimmune disease,…
August 1, 2022 - 4 minutes
BioMed X Institute and Merck start new oncology research project
BioMed X, a German independent research institute, has started a new research project ‘Extrachromosomal DNA…
August 1, 2022 - 3 minutes
